PCOS in India: The Scale of the Problem
PCOS is the most common endocrine disorder in Indian women of reproductive age. Community studies put prevalence between 9 and 22 percent depending on diagnostic criteria, and clinic-based numbers run higher. The condition is not a cosmetic inconvenience. It is a metabolic disease that announces itself through irregular periods, acne, hirsutism, and unwanted weight, then progresses quietly into insulin resistance, fatty liver, and type 2 diabetes.
What makes the Indian presentation distinct is body composition. Misra and colleagues described in JAPI 2009 a phenotype now widely recognised as thin-fat: a normal or only modestly elevated BMI with disproportionately high visceral fat, low lean mass, and early insulin resistance. ICMR-INDIAB-17 (Anjana et al., Lancet Diabetes and Endocrinology 2023) confirmed that Indians develop dysglycaemia at lower BMIs than Western populations. A woman in Kochi with a BMI of 24 can carry the metabolic load of a woman in Boston at 30. PCOS sits squarely on top of this biology.
PCOS in India is not a weight problem that occasionally produces metabolic disease. It is a metabolic disease that produces a weight problem.
Why Standard PCOS Advice Falls Short
The standard prescription for a young Indian woman with PCOS has been the same for two decades. Lose weight. Take metformin. Consider an oral contraceptive to regulate cycles. Come back in six months.
Each of these has merit, and none is sufficient on its own.
Weight loss advice, when it stops at "eat less and walk more", ignores the biology of insulin resistance. Hunger and satiety in a woman with PCOS are not character traits. They are downstream of hormones she did not choose. Metformin lowers fasting insulin and modestly improves cycles, but produces only 2 to 3 kg of average weight loss and does little for the woman whose primary problem is appetite and visceral fat. The combined oral contraceptive regularises bleeding by overriding the hypothalamic-pituitary-ovarian axis. It does not treat insulin resistance. It often masks the underlying disease while the metabolic clock keeps ticking.
The result is a generation of educated Indian women who have been told they have PCOS, given a prescription, and left to feel that their inability to "just lose weight" is a personal failing. It is not.
How GLP-1 Therapy Changes the PCOS Conversation
GLP-1 receptor agonists were designed for type 2 diabetes and refined for obesity. Their relevance to PCOS is not coincidental. They act on exactly the biological levers that drive the syndrome.
Insulin sensitivity, the upstream lever
GLP-1 agonists enhance glucose-dependent insulin secretion and suppress glucagon. The downstream effect over weeks is a measurable fall in fasting insulin and HOMA-IR. In a woman with PCOS, falling insulin reduces ovarian androgen production and increases hepatic SHBG, which lowers free testosterone in circulation. This is the same mechanism metformin targets, but the magnitude of effect with GLP-1 therapy is larger.
Weight loss and androgen reduction
In the STEP 1 trial (Wilding et al., NEJM 2021;384:989), semaglutide 2.4 mg produced a mean weight reduction of 14.9 percent over 68 weeks. In SURMOUNT-1 (Jastreboff et al., NEJM 2022;387:205), tirzepatide produced up to 20.9 percent at the highest dose. These trials were not run in PCOS populations, and that limitation matters. But weight loss of this magnitude in any insulin-resistant woman reliably reduces hyperandrogenism. Acne improves. Hirsutism slows. The hairline thickens.
Menstrual regulation
When weight falls and insulin sensitivity improves, ovulation often returns. In clinical practice I see cycles re-establish within the first three to six months in women who had been amenorrhoeic for years. This is not a guarantee, and it is not the same as treating infertility, but it is a meaningful clinical signal that the disease is moving in the right direction.
Inflammation and the cardiometabolic axis
PCOS is a low-grade inflammatory state. Visceral fat secretes inflammatory cytokines that worsen insulin resistance and accelerate atherosclerosis. Reducing visceral adiposity reduces this signal at its source. The 2023 international PCOS guideline recognises cardiometabolic risk reduction as a primary therapeutic goal, not a secondary benefit.
What the Evidence Actually Shows
Honesty matters here. As of today there are no large randomised trials of semaglutide or tirzepatide conducted exclusively in PCOS populations with reproductive endpoints. Smaller studies and meta-analyses of liraglutide and exenatide in PCOS women show consistent improvements in weight, HOMA-IR, free androgen index, and menstrual frequency. The newer agents almost certainly do better, but the formal PCOS-specific evidence base is still being built.
What we do have is robust weight loss data from STEP 1 and SURMOUNT-1, decades of mechanistic understanding of PCOS, and the 2023 international guideline (Teede et al.) endorsing weight reduction as central therapy. We extrapolate carefully and we monitor closely. That is medicine.
Fertility Planning and the Two-Month Rule
This is the conversation no one starts but every woman of reproductive age needs. GLP-1 medications carry an FDA-required label instructing women to discontinue at least two months before attempting conception. The reason is pharmacokinetic. Semaglutide has a half-life of approximately one week and a long tail. Reproductive safety data in humans is insufficient.
For an Indian woman in her late twenties or early thirties, this changes the planning calendar. If a wedding is six months away and a pregnancy is hoped for within the first year of marriage, GLP-1 therapy may still be appropriate, but the exit ramp must be designed at the start, not improvised at the end. We map this out at the first consultation.
Rotterdam Criteria: Who Actually Has PCOS
A patient is considered to have PCOS under the Rotterdam framework if she meets two of three criteria. Other causes of these features (thyroid disease, hyperprolactinaemia, congenital adrenal hyperplasia, Cushing) must be excluded first. We do not start a metabolic therapy on the basis of irregular cycles alone.
Rotterdam Criteria. Two of three required.
- Oligomenorrhoea or anovulation.
- Clinical or biochemical hyperandrogenism.
- Polycystic ovarian morphology on ultrasound.
The DermaVue PCOS and GLP-1 Protocol
Baseline workup
Before any prescription is written, every patient completes a structured panel. Each result changes the conversation.
Monitoring cadence
After initiation, we review at week 4, week 8, and week 12, then every 8 to 12 weeks. We re-check HbA1c, insulin, lipids, and androgens at three months. We track body composition, not just scale weight, because preserving lean mass is the difference between a successful protocol and a regretted one.
Face-Saver consideration during rapid weight loss
Rapid weight loss in a woman whose face carries midline volume can produce a hollowed appearance that no patient wants. Our Face-Saver protocol pairs metabolic care with structured collagen support and selective volume preservation through the dermatology arm of the practice. It is a small intervention with a large quality-of-life return. We discuss it at week 8, before the changes are visible.
What to Expect in the First Twelve Weeks
Weeks one to two are usually quiet. Appetite begins to fall. Some women feel mildly nauseous in the evenings. Weeks three to six are the titration window, and side effects, when they occur, are most likely here. Cravings for refined carbohydrate fall noticeably. Energy stabilises. By week eight, many women report a quiet but unmistakable shift in their relationship with food. By week twelve, body composition has begun to reorganise, the first menstrual changes may appear, and the lab numbers usually start to confirm what the patient already feels.
When GLP-1 Is Not the Right Choice
Active pregnancy planning within two months. Personal history of medullary thyroid carcinoma or MEN-2. Personal history of pancreatitis. An active eating disorder, particularly restrictive subtypes. Severe gastroparesis. In each of these situations the answer is no, or not yet, and we say so plainly. There are other tools.
Generic GLP-1 Update. March 2026
Generic semaglutide entered the Indian market in March 2026. Branded Ozempic at 0.5 mg weekly previously ran around Rs 8,100 per month. Indian generics from Natco, Alkem, and Dr. Reddy's now sit between Rs 1,290 and Rs 4,200 at the same dose. The molecule and safety profile are identical. Physician supervision is still required because GLP-1 therapy carries real contraindications. Cheaper does not mean safer to self-prescribe.